Premium
Autologous hematopoietic stem cell transplant in a patient with leprosy: Is it safe?
Author(s) -
Salomão Matias Chiarastelli,
Batista Marjorie Vieira,
Macedo Maria Cristina,
Sotto Mirian Nacagami,
Duarte Amaro Nunes,
Rocha Vanderson Geraldo,
Higashino Hermes Ryoiti,
Costa Silvia Figueiredo
Publication year - 2018
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12840
Subject(s) - medicine , leprosy , doxycycline , hematopoietic stem cell transplantation , lymphoma , stem cell , rifampicin , hematopoietic stem cell , ofloxacin , surgery , haematopoiesis , transplantation , immunology , antibiotics , tuberculosis , pathology , ciprofloxacin , genetics , microbiology and biotechnology , biology
A patient with non‐Hodgkin lymphoma, preparing for an autologous hematopoietic stem cell transplant ( HSCT ), developed leprosy. The patient was successfully treated with rifampicin, ofloxacin, and doxycycline, and the HSCT was performed without complications, being the first report, to our knowledge, of leprosy in an autologous HSCT patient.